Recardio, founded in San Francisco, California, is a clinical-stage life science company dedicated to developing innovative treatments for cardiovascular, cancer, and infectious diseases. The company's core mission is to enhance patient outcomes through regenerative therapeutic modalities, particularly focusing on cardiovascular health. Their primary product, dutogliptin, is a DPP-IV inhibitor that activates chemokines such as SDF-1, crucial for cardiac regeneration. Recardio operates in both the USA and Europe, aiming to improve heart function, quality of life, and survival rates for patients with conditions like acute myocardial infarction and chronic heart failure.

Notable figures associated with Recardio include leading scientists and medical professionals in the field of cardiovascular research. The company has attracted significant interest from investors focused on life sciences and medical innovations. Key achievements include advancing dutogliptin to late clinical-stage trials, demonstrating its potential in regenerative medicine. Recardio's impact lies in its pioneering approach to cardiac therapy, offering hope for improved treatments and outcomes in cardiovascular disease management.